Update on Charles River’s collaboration with Moderna Therapeutics
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
List view / Grid view
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
‘Paediatric Clinical Trials’ returns to London on 20th-21st March 2017 and is delighted to have Larissa Kerecuk as one of the keynote speakers.
24 January 2017 | By
Author and Scientific Director Jean de Gunzburg, from Da Volterra, will present keynote speech at 19th annual Superbugs summit...
Organ models, which are cultivated in the laboratory from human stem cells and grow into living tissue, are one of the most important scientific breakthroughs of recent years.
Ligands are useful tools for studying how proteins work in cells and could lead to the development of new drugs.
Researchers have made a ground-breaking discovery revealing new molecular information on how the brain regulates depression and anxiety.
The designation certifies that Exco InTouch’s practices meet or exceed the data privacy and security principles outlined by US Department of Commerce and European Commission.
Cell2Sphere is the first simple 3D tissue culture kit for labs interested in more accurate, scalable and dynamic experimental research.
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20% increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland.
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
Information on significant properties of pharmaceutical tablets, such as their mechanical strength and dissolution, can now be obtained without resorting to the conventional, time-consuming and destructive testing methods, according to a new study completed at the University of Eastern Finland.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.